(CercleFinance.com) – Pfizer said on Friday that it had completed the acquisition of Arena Pharmaceuticals, a clinical-stage biotechnology company which it had initially announced the acquisition last December.
Arena’s portfolio includes various development-stage therapeutic candidates in gastroenterology, dermatology and cardiology.
Phase 3 results on etrasimod, its lead drug candidate, are expected in the treatment of ulcerative colitis by the end of the month.
The acquisition was completed for a total value of $6.7 billion.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
